Automated Manufacturing Collaboration for TSC-101: Cellares and TScan Therapeutics Inc. Partner to Enhance Cell Therapy Production
Cellares and TScan Therapeutics Inc. have entered into a collaboration to explore the automated manufacturing of TSC-101, TScan's leading T cell receptor-engineered T cell therapy candidate for acute myeloid leukemia and myelodysplastic syndromes. The partnership will evaluate Cellares' Cell Shuttle and Cell Q platforms for producing TSC-101, which is intended to address residual disease and prevent relapse in patients undergoing allogeneic hematopoietic cell transplantation. TScan is set to commence a pivotal trial for TSC-101 in the second quarter of 2026.
As part of the agreement, Cellares will automate the manufacturing and testing processes for TSC-101 using its comprehensive manufacturing platform and automated quality control system. The closed-system workflows are designed to enhance consistency in processes and reduce labor requirements. TScan's Chief Manufacturing and Quality Officer, Ray Lockard, emphasized the importance of establishing a scalable and cost-effective manufacturing strategy as the company gears up for its pivotal study. The goal is to assess how this technology can support TScan's manufacturing network and improve patient access.
TSC-101 employs a gene modification technique to transform T cells from healthy donors into personalized cell therapy products for patients with blood cancers who are at risk of relapse post-transplant. This collaboration broadens Cellares' range of offerings to include TCR-engineered T cell therapies in addition to CAR-T cell therapies, hematopoietic stem cell programs, and autologous progenitor T cell therapies. Cellares functions as an Integrated Development and Manufacturing Organization, delivering cell therapy development and manufacturing services.
In conclusion, the collaboration between Cellares and TScan Therapeutics Inc. to explore automated manufacturing for TSC-101 represents a significant step in advancing T cell therapy for patients with blood cancers. The partnership aims to streamline manufacturing processes, enhance quality control, and ultimately improve patient outcomes in the treatment of acute myeloid leukemia and myelodysplastic syndromes.